CB Therapeutics

CB Therapeutics is a private, San Diego-based synthetic biology firm developing a proprietary yeast fermentation platform for the sustainable production of cannabinoids, psychedelics, and food-tech ingredients. The company is in an early-revenue stage, supplying molecules for research and commercial use while building a state-of-the-art manufacturing facility. Key strategic moves include a partnership with atai Life Sciences (TryptageniX) and the formation of a Medical Advisory Board, positioning it at the intersection of mental health therapeutics and sustainable manufacturing.

Proprietary yeast-based precision fermentation platform for biosynthesizing cannabinoids, psychedelic tryptamines, and food ingredients.

CB Therapeutics competes with a range of synthetic biology companies like Ginkgo Bioworks and Amyris, as well as specialized firms focused on fermenting cannabinoids (e.g., Demetrix, Cronos Group's Ginkgo partnership) and psychedelics (e.g., Octarine Bio, Compass Pathways' supply chain). Its differentiation lies in its specific focus on tryptamines and cannabinoids within a broader sustainability narrative.